Humana Stock Analysis

Sell This Insurer…

A bull/bear case for Humana Inc. centers on a convergence of structural, regulatory, and execution risks that threaten both near-term earnings and long-term valuation. As you can see from the chart below, Humana has lost all of its gains since October 2016. Worse, the company is years away from righting the ship.

So, what’s going on with this heavy-duty health insurer?

First, Humana is heavily concentrated in Medicare Advantage (MA), a market that is becoming less profitable. Elevated medical utilization, a high medical loss ratio along with weaker Star Ratings are pressuring earnings and reducing near-term profitability.

On top of this, recent changes to MA reimbursement rates from Centers for Medicare & Medicaid Services have been less generous than insurers expected, compressing margins across the industry. This combination of weaker revenue growth and rising expenses creates a classic margin squeeze that is difficult to offset quickly.

Now, Humana’s decline in MA Star Ratings is a significant structural headwind – which will cost the company billions. These ratings directly determine bonus payments and influence enrollment growth. Lower ratings not only reduce current revenue but also make plans less competitive in future enrollment cycles. 

Worse, rebuilding Star Ratings is a multi-year process involving operational improvements, member experience enhancements, and clinical outcomes—none of which provide immediate financial relief. This creates a lag where profitability deteriorates faster than management can fix underlying issues.

Another major headwind for the company involves growing regulatory and legal scrutiny. While not yet crystallized into a major enforcement action, ongoing investigations and lawsuits related to disclosures and billing practices introduce headline risk and potential financial liabilities. Even if these cases are ultimately resolved without major penalties, they can increase compliance costs, distract management, and weigh on investor sentiment.

Thus, Humana’s strategic positioning leaves it less diversified than peers like UnitedHealth Group or CVS Health. Those companies have broader ecosystems—including pharmacy benefit management, provider networks, and diversified insurance lines—that help offset pressure in any one segment. Humana’s reliance on MA means it is more exposed to policy changes and demographic cost trends, with fewer internal levers to stabilize earnings.

The company’s earnings have deteriorated meaningfully. Management’s forward guidance has disappointed investors, reflecting uncertainty in both cost trends and reimbursement dynamics. The company’s reported adjusted EPS for FY 2025 was $17.14, while FY 2026 guidance was reset to at least $9.00 adjusted EPS, reflecting the severity of the earnings headwind.

When a company cannot reliably forecast its own earnings trajectory, markets tend to assign a lower valuation multiple. This creates downside risk even if absolute earnings do not collapse.

Finally, valuation may not yet fully reflect these risks. While the stock has declined, it could still face multiple compression if margins continue to erode and growth slows. Investors who previously valued Humana as a stable, high-quality compounder may reassess it as a more cyclical, policy-sensitive business.

In sum, the bearish thesis is not about a single catastrophic event but rather a sustained deterioration in fundamentals: tighter government payments, higher medical costs, weaker competitive positioning, and limited diversification—all of which could pressure Humana’s earnings and stock performance for several years.

So what is a fair value for Humana stock?

Using a simple DCF valuation framework for Humana (HUM) using the latest guidance and market data available, Humana’s 2026 earnings are being reset lower, making this DCF best treated as a scenario model due to current projections of just $393 million in Free Cash Flow (FCF) in 2026 and a paltry $404 million in 2027.  Free cash flow is one of the best indicators of a company’s health – and Humana’s numbers are abysmal.

Assumptions used

• Starting revenue base: FY 2025 revenue of $129.7 billion.
• FY 2026 earnings guide: at least $9.00 adjusted EPS and at least $8.89 GAAP EPS.
• Shares outstanding: about 120.3 million.
• Market cap reference: about $21.0 billion in late March 2026.
• Tax rate reference: recent effective tax rate about 17.2%.

DCF model

Since Humana is an insurer, a classic operating DCF based on EBITDA is less clean than for an industrial company. For a practical stock DCF, I used a free cash flow to equity-style approach and anchored near current earnings power, then modeled moderate recovery over five years. The key uncertainty is conversion of earnings into cash flow because 2025 free cash flow was only about $375 million while earnings were much larger.

Base-case valuation

Using those assumptions, Humana’s implied equity value is roughly $130 - $150 per share, a discount of 9.64% to 21.69% to current values.  This stock is a sell.

‍